Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
    • COVID-19 submission information
  • Alerts
  • Subscriptions

How to handle oligometastatic disease in nonsmall cell lung cancer

Florian Eichhorn, Hauke Winter
European Respiratory Review 2021 30: 200234; DOI: 10.1183/16000617.0234-2020
Florian Eichhorn
1Dept of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany
2Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hauke Winter
1Dept of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany
2Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hauke.winter@med.uni-heidelberg.de
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Tables

  • TABLE 1

    Clinical trials investigating oligometastatic disease

    IdentifierTitleDescriptionAllocationStatus
    NCT03965468Immunotherapy, chemotherapy, radiotherapy and surgery for synchronous oligo-metastatic NSCLCImmunotherapy, chemotherapy plus stereotactic radiotherapy to synchronous oligo-metastases followed by definitive surgery or radiotherapy to primary NSCLCRecruiting
    NCT03827577OMEGA, local ablative therapy in oligometastatic NSCLCResection of primary NSCLC plus local ablative therapy to all metastases versus standard-of-care chemotherapyRandomisedRecruiting
    NCT03275597Phase Ib study of stereotactic body radiotherapy (SBRT) in oligometastatic non-small lung cancer (NSCLC) with dual immune checkpoint inhibitionSBRT followed by combined durvalumab and tremelimumabRecruiting
    NCT03119519Local non-salvage radiotherapy for synchronous oligometastatic non-small-cell lung cancerChemotherapy plus local definitive radiotherapy to primary and oligo-metastases versus standard-of-care chemo-/targeted-therapyRandomisedRecruiting
    NCT02975609Phase II trial of SBRT compared with conventional radiotherapy for oligometastatic non-small cell lung cancerChemotherapy plus SBRT versus chemotherapy plus conventional fractionated radiotherapy to primary and all metastatic sitesRandomisedNot yet recruiting
    NCT02417662Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancerPatients will be randomised to receive either standard chemotherapy treatment alone or standard treatment with conventional radiotherapy and SABRRandomisedRecruiting
    NCT02054819Treating NSCLC minimal stage IV with curative intentPlatinum-based chemotherapy with concurrent radiation therapy to the primary tumour and identified mediastinal lymph nodal metastatic drainage. Local curative radiation will then target the oligometastatic tumour sitesTerminated (low accrual)
    NCT01185639Stereotactic body radiation therapy (SBRT) in metastatic non-small cell lung cancerChemotherapy followed by local ablative radiotherapy to all metastatic lesionsCompleted

    NSCLC: nonsmall cell lung cancer; SBRT: stereotactic body radiotherapy; SABR: stereotactic ablative radiotherapy.

    PreviousNext
    Back to top
    View this article with LENS
    Vol 30 Issue 159 Table of Contents
    European Respiratory Review: 30 (159)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    How to handle oligometastatic disease in nonsmall cell lung cancer
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Alerts
    Sign In to Email Alerts with your Email Address
    Citation Tools
    How to handle oligometastatic disease in nonsmall cell lung cancer
    Florian Eichhorn, Hauke Winter
    European Respiratory Review Mar 2021, 30 (159) 200234; DOI: 10.1183/16000617.0234-2020

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    How to handle oligometastatic disease in nonsmall cell lung cancer
    Florian Eichhorn, Hauke Winter
    European Respiratory Review Mar 2021, 30 (159) 200234; DOI: 10.1183/16000617.0234-2020
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • Abstract
      • Abstract
      • Introduction
      • Definition of the oligmetastatic situation and prognostic implications
      • Ablative techniques in the treatment of oligometastases
      • Lung oligometastases
      • Brain metastases
      • Adrenal metastases
      • Bone metastases
      • Other extrathoracic locations
      • The role of systemic treatment of oligometastatic disease
      • Current patient selection and prognostic factors
      • Ongoing clinical trials
      • Conclusion and future directions
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF

    Subjects

    • Lung cancer
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    Series

    • Biology and management of mesothelioma
    • Advances in pleural infection and malignancy
    Show more Series

    Thoracic oncology

    • Biology and management of mesothelioma
    Show more Thoracic oncology

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERR

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising
    • Sponsorship

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Submit a manuscript
    • ERS author centre

    For readers

    • Alerts
    • Subjects
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN: 0905-9180
    Online ISSN: 1600-0617

    Copyright © 2021 by the European Respiratory Society